Disease-free survival (DFS) as a surrogate for overall survival (OS) in patients (pts) with HR+/HER2-early breast cancer (EBC): A correlation analysis.

被引：0
|
作者：
Untch, Michael
Perol, David
Mayer, Erica L.
Cortes, Javier
Nusch, Arnd
Cameron, David A.
Barrios, Carlos
Delea, Thomas E.
Salas, Tonatiuh Romero
Kalra, Manik
Gupta, Rhea
Pathak, Purnima
Fasching, Peter A.
机构：
[1] Helios Klinikum Berlin Buch, Interdisciplinary Breast Canc Ctr, Berlin, Germany
[2] Ctr Leon Berard, Dept Clin Res, Lyon, France
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Int Breast Canc Ctr, Quiron Grp, Barcelona, Spain
[5] Univ Edinburgh, Edinburgh Canc Res Ctr, Edinburgh, Midlothian, Scotland
[6] Latin Amer Cooperat Oncol Grp LACOG, Porto Alegre, RS, Brazil
[7] Policy Anal Inc, Chestnut Hill, MA USA
[8] Novartis Pharmaceut, E Hanover, NJ USA
[9] Novartis Healthcare Pvt Ltd, Hyderabad, India
[10] Univ Hosp Erlangen, Dept Obstet & Gynecol, Erlangen, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
535
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Disease-free survival as a surrogate for overall survival in HR+/HER2-early breast cancer: A correlation analysis
    Untch, Michael
    Perol, David
    Mayer, Erica L.
    Cortes, Javier
    Nusch, Arnd
    Cameron, David
    Barrios, Carlos
    Delea, Thomas
    Danyliv, Andrii
    Mishra, Namita
    Gupta, Rhea
    Pathak, Purnima
    Fasching, Peter A.
    EUROPEAN JOURNAL OF CANCER, 2024, 202
  • [2] Correlation analysis of invasive disease-free survival and overall survival in a real-world population of patients with HR+/HER2-early breast cancer
    Graff, Stephanie L.
    Tolaney, Sara M.
    Hart, Lowell L.
    Razavi, Pedram
    Janni, Wolfgang
    Schwartzberg, Lee S.
    Danyliv, Andriy
    Akdere, Murat
    Ferrusi, Ilia
    Adhikary, Rishi Rajat
    O'Shaughnessy, Joyce A.
    CANCER, 2025, 131 (07)
  • [3] Abemaciclib Improves Disease-Free Survival in High-Risk HR+/HER2-Early Breast Cancer
    不详
    ONCOLOGIST, 2021, 26 : S5 - S6
  • [4] Disease-free survival (DFS) as surrogate end-point for overall survival (OS) in early breast cancer (EBC): Correlation may be different according to drugs and/or strategies tested
    Giannarelli, D.
    Bria, E.
    Carlini, P.
    Di Maio, M.
    Cuppone, F.
    Sperduti, I.
    Nistico, C.
    Vaccaro, V.
    Terzoli, E.
    Cognetti, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] DISEASE-FREE SURVIVAL (DFS) AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL (OS) IN HER2 NEGATIVE (HER2-) PRIMARY BREAST CANCER (BC)
    McCrea, C.
    Chatzidaki, I
    Drane, E.
    McArthur, E.
    Beaver, S.
    Reason, T.
    Gulati, P.
    VALUE IN HEALTH, 2020, 23 : S425 - S425
  • [6] Disease-free survival (DFS) as a surrogate for overall survival (OS) in localized prostate cancer (CaP).
    Sweeney, Christopher
    Xie, Wanling
    Regan, Meredith M.
    Nakabayashi, Mari
    Buyse, Marc E.
    Clarke, Noel W.
    Collette, Laurence
    Dignam, James J.
    Fizazi, Karim
    Habibian, Muriel
    Halabi, Susan
    Kantoff, Philip W.
    Parulekar, Wendy R.
    Sandler, Howard M.
    Sartor, Oliver
    Soule, Howard R.
    Sydes, Matthew Robert
    Tombal, Bertrand F.
    Williams, Scott G.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Evaluation of disease-free survival (DFS) as a surrogate for overall survival (OS) in the adjuvant therapy of HER2-positive early breast cancer (EBC) calls for individual-patient data (IPD)
    Saad, E.
    Delaloge, S.
    Mavroudis, D.
    Perez, E.
    Piccart-Gebhart, M.
    Schneider, B.
    Wolmark, N.
    Buyse, M.
    Burzykowski, T.
    BREAST, 2017, 32 : S26 - S26
  • [8] Impact of chemotherapy-induced ovarian failure (CIOF) on disease-free survival (DFS) and overall survival (OS) in young women with early breast cancer (EBC)
    Furlanetto, J.
    Nekljudova, V.
    Schneeweiss, A.
    Thode, C.
    Denkert, C.
    Untch, M.
    Bassy, M.
    Karn, T.
    Fasching, P. A.
    Stickeler, E.
    Schem, C.
    Marme, F.
    Grischke, E. -M.
    van Mackelenbergh, M.
    Strik, D.
    Schmatloch, S.
    Mueller, V.
    Loibl, S.
    ANNALS OF ONCOLOGY, 2019, 30 : 57 - +
  • [9] Impact of Chemotherapy-Induced Ovarian Failure (CIOF) on Disease-Free Survival (DFS) and Overall Survival (OS) in Young Women with Early Breast Cancer (EBC)
    Furlanetto, Jenny
    Nekljudova, Valentina
    Schneeweiss, Andreas
    Thode, Christian
    Denkert, Carsten
    Untch, Michael
    Bassy, Martina
    Karn, Thomas
    Fasching, Peter A.
    Stickeler, Elmar
    Schem, Christian
    Marme, Frederik
    Grischke, Eva-Maria
    van Mackelenbergh, Marion
    Strik, Dorninika
    Schmatloch, Sabine
    Mueller, Volkmar
    Loibl, Sibylle
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 6 - 6
  • [10] Correlation between pathologic complete response, event-free survival/disease-free survival and overall survival in neoadjuvant and/or adjuvant HR+/HER2-breast cancer
    Gogate, Anagha
    Ranjan, Sandip
    Kumar, Amit
    Bhandari, Hitesh
    Papademetriou, Eros
    Kim, Inkyu
    Potluri, Ravi
    FRONTIERS IN ONCOLOGY, 2023, 13
12345